Camillo Porta

mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy

S. Pedron, A. Caliò, M. Brunelli, 2023, Virchows Archiv.

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

S. Salah, R. Kanesvaran, P. Giannatempo, 2024, Scientific reports.

Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience

M. Cives, Antonella Centonza, E. Lauricella, 2024, Clinical and experimental medicine.